DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lotronex (Alosetron Hydrochloride) - Published Studies

 
 



Lotronex Related Published Studies

Well-designed clinical trials related to Lotronex (Alosetron)

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. [2007.08]

The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome. [2005.04]

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. [2005.01]

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. [2004.11]

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. [2004.08]

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. [2002.12]

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. [2002.10]

The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. [2002.07]

Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. [2002.05]

Sex and age differences in the pharmacokinetics of alosetron. [2002.03]

Effect of alosetron on theophylline pharmacokinetics. [2001.11]

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. [2001.09]

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. [2001.07.23]

Effect of alosetron on the pharmacokinetics of alprazolam. [2001.04]

A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. [2001.04]

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. [2001.03]

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. [2001.02]

Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. [2000.07]

Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. [2000.06]

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. [2000.03.25]

Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. [2000.01]

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. [1999.11]

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. [1999.09]

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. [1998.09]

Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea. [1998.05]

In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. [1997.12]

Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients. [1995.02]

Alosetron does not affect the visceral perception of gastric distension in healthy subjects. [1994.08]

Well-designed clinical trials possibly related to Lotronex (Alosetron)

The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. [2012]

Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study. [2008.08.01]

A Phase II Trial of the Novel Serotonin Type 3 Receptor Antagonist Ramosetron in Japanese Male and Female Patients with Diarrhea-Predominant Irritable Bowel Syndrome. [2008.06.10]

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. [2008.05]

Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [2008.01.30]

A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. [2008]

Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. [2006.07.15]

Evaluation of drug treatment in irritable bowel syndrome. [2003.10]

Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors. [2003.01]

Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans. [2002.02]

Other research related to Lotronex (Alosetron)

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. [2012]

Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. [2011.03]

Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. [2010.06]

Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. [2010.04]

Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. [2010.02]

Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats. [2009.11]

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A meta-analysis of eight randomized, placebo-controlled, 12-week trials. [2008.05]

A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of 0.5 mg and 1 mg Alosetron in Women With Severe Diarrhea-predominant IBS. [2007.05.17]

The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. [2007.02.01]

Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia. [2006.12.15]

A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. [2006.09.01]

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. [2006.05]

Acute hepatitis associated with alosetron (Lotronex). [2005.08]

Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex). [2004.08]

Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors. [2004.07.15]

Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? [2004]

Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. [2003.12]

Alosetron and irritable bowel syndrome. [2003.11]

Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. [2003.05]

Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. [2003.04]

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. [2003.02]

Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder. [2003]

Ischemic colitis during treatment with alosetron. [2001.02]

Alosetron. [2000.03]

Pharmacology and clinical experience with alosetron. [2000.01]

The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. [1999.06]

Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. [1999.05]

Review article: clinical pharmacology of alosetron. [1999.05]

Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist. [1999.01]

Other possibly related research studies

Pharmacological treatment of irritable bowel syndrome--from concept to sales. [2002]

[Irritable bowel syndrome: a concise diagnostic and pharmacological therapy review] [2005.04]

Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. [2005.02]

Irritable bowel syndrome. 10% to 20% of older adults have symptoms consistent with diagnosis. [2005.01]

Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies. [2004.12]

5-HT3-receptor antagonist inhibits visceral pain differently in chemical and mechanical stimuli in rats. [2004.01]

Advances in the management of irritable bowel syndrome. [2003.12]

Tegaserod and other serotonergic agents: what is the evidence? [2003]

New developments in the diagnosis and treatment of irritable bowel syndrome. [2002.10]

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. [2002.08]

Serotoninergic neuroenteric modulators. [2001.12.15]

The challenge of irritable bowel syndrome: creating an alliance between patient and physician. [2001.03]

New therapies for functional bowel diseases. [2000.10]

Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. [1999.05]

Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. [1999.05]

Treatment of irritable bowel syndrome. [2005.12.15]

Diagnosis and treatment of irritable bowel syndrome: state of the art. [2005.08]

Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. [2005.06]

Psychotherapeutics and serotonin agonists and antagonists. [2005.05]

Rationale for using serotonergic agents to treat irritable bowel syndrome. [2005.04.01]

Meta-analysis: The treatment of irritable bowel syndrome. [2004.12]

Spectrum of use and tolerability of 5-HT3 receptor antagonists. [2004]

Diagnostic and therapeutic strategies in the irritable bowel syndrome. [2004.10]

Functional dyspepsia: drugs for new (and old) therapeutic targets. [2004.08]

Colonic toxicity of administered drugs and chemicals. [2004.06]

The brain-gut axis in irritable bowel syndrome--clinical aspects. [2004.06]

Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. [2004.04]

Treating irritable bowel syndrome: overview, perspective and future therapies. [2004.04]

Safety and tolerability of tegaserod in irritable bowel syndrome management. [2004.01]

Gateways to clinical trials. [2003.10]

Gateways to clinical trials. [2003.01]

[Visceral hypersensitivity: a concept within our reach] [2003.01]

Gateways to clinical trials. [2002.10]

Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. [2002.07]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012